Pharmacokinetic parameters of chlorzoxazone and its main metabolite, 6-hydroxychlorzoxazone, after intravenous and oral administration of chlorzoxazone to liver cirrhotic rats with diabetes mellitus

Drug Metabolism and Disposition

Volumn 36, Issue 7, 2008, Pages 1233-1241

  Ahn, Choong Y ^a,b   Bae, Soo K ^a,c   Jung, Young S ^a   Lee, Inchul ^d   Kim, Young C ^a   Lee, Myung G ^a   Shin, Wan G ^a  

^a Seoul National University   (South Korea)

^b Korea Food and Drug Administration   (South Korea)

^c Inje University College of Medicine   (South Korea)

^d Asan Medical Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

6 HYDROCHLORZOXAZONE; CHLORZOXAZONE; CYTOCHROME P450 2E1; DIMETHYLNITROSAMINE; DRUG METABOLITE; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD CHEMISTRY; BODY WEIGHT; CONTROLLED STUDY; DIABETES MELLITUS; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; KIDNEY FUNCTION; LIVER CIRRHOSIS; LIVER FUNCTION; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NONHUMAN; ORGAN WEIGHT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SPLEEN FUNCTION; TIME TO MAXIMUM PLASMA CONCENTRATION; URINE VOLUME; WESTERN BLOTTING;

ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; BLOOD PROTEINS; CHLORZOXAZONE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIABETES MELLITUS, EXPERIMENTAL; INFUSIONS, INTRAVENOUS; KIDNEY; LIVER; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; SPLEEN;

RATTUS;

EID: 46449110216     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.017442     Document Type: Article

References (40)

1. Bae SK, Lee SJ, Kim T, Kim JW, Lee I, Kim SG, and Lee MG (2006) Pharmacokinetics and therapeutic effects of oltipraz after consecutive or intermittent oral administration in rats with liver cirrhosis induced by dimethylnitrosamine. J Pharm Sci 95:985-997.
2. Baek HW, Bae SK, Lee MG, and Shon YT (2006) Pharmacokinetics of chlorzoxazone in rats with diabetes: induction of CYP2E1 on 6- hydroxychlorzoxazone formation. J Pharm Sci 95:2452-2462.
3. Boudinot FD and Jusko WJ (1984) Fluid shifts and other factors affecting plasma protein binding of prednisolone by equilibrium dialysis. J Pharm Sci 73:774-780.
4. Bradford MM (1976) A rapid and sensitive method for the quantitalion of rnicrogram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
5. Carriere V, Goasduff T, Ratanasavanh D, Morel F, Gautier JC, Guillouza A, Geaune P, and Berthou F (1993) Both cytochromes P450 2E1 and 1A1 are involved in the metabolism of chlorzoxazone. Chem Res Toxicol 6:852-857.
6. Chiou WL (1978) Critical evaluation of potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J Pharmacokinet Biopharm 6:539-549.
7. Chung HC, Kim SH, Lee MG, Cho CK, Kim TH, Lee DH, and Kim SG (2001) Mitochondrial dysfunction by gamma-irradiation accompanies the induction of cytochrome P450 2E1 (CYP2E1) in rat liver. Toxicology 161:79-91.
8. Conney AH and Burns JJ (1960) Physiological disposition and metabolic fate of chlorzoxazone (Paraflex) in man. J Pharmacol Exp Ther 128:340-343.
9. Davics B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095.
10. Desiraju RK, Renzi NL Jr, Nayak RK, and Ng KT (1983) Pharmacokinetics of chlorzoxazone in humans. J Pharm Sci 72:991-994.
11. Frye RF and Stiff DD (1996) Determination of chlorzoxazone and 6-hydroxychlorzoxazone in human plasma and urine by high-performance liquid chromatography. J Chromatogr B 686:291-296.
12. Gibaldi M and Perrier D (1982) Pharmacokinetics, 2nd ed, Marcel-Dekker, Inc., New York.
13. Gorski JC, Jones DR, Wrighton SA, and Hall SD (1997) Contribution of human CYP3A subfamily members to the 6-hydroxylation of chlorzoxazone. Xenobiotica 27:243-256.
14. Jayyosi Z, Knoble D, Muc M, Erick J, Thomas PE, and Kelley M (1995) Cytochrome P-450 2E1 is not the sole catalyst of chlorzoxazone hydroxylation in rat liver microsornes. J Pharmacol Exp Ther 273:1156-1161.
15. Jenkins SA, Grandison A, Baxter JN, Day DW, Taylor I, and Shields R (1985) A dimethylnitrosamine-induced model of cirrhosis and portal hypertension in the rat. J Hepatol 1:489-499.
16. Jezequel AM, Mancini R, Rinaldesi ML. Macarri G, Venturini C, and Orlandi F (1987) A morphological study of the early stages of hepatic fibrosis induced by low doses of dimethylnitrosamine in the rat. J Hepatol 6:174-181.
17. Johansson I, Lindros KO, Eriksson K, and Ingelman-Sundberg M (1990) Transcriptional control of CYP2E1 in the perivenous liver region and during starvation. Biochem Biophys Res Comnun 173:331-338.
18. Kang KW, Kim YG, Cho MK, Bae SK, Kim CW, Lee MG, and Kim SG (2002) Oltipraz regenerates cirrhotic liver through CCAAT/enhancer binding protein-mediated stellate cell inactivation. FASEB J 16:1988-1990.
19. Kim SG, Kim EJ, Kim YG, and Lee MG (2001) Expression of cytochrome P-450s and glutathione S-transferases in the rat liver during water deprivation: effects of glucose supplementation. J Appl Toxicol 21:123-129.
20. Kim YC, Lee AK, Lee JH, Lee I, Lee DC, Kim SH, Kim SG, and Lee MG (2005) Pharmacokinetics of theophylline in diabetes mellitus rats: induction of CYP2E1 on 1,3-dimethyluric acid formation. Eur J Pharm Sci 26:114-123.
21. Kwon SY (2003) Prevalence and clinical significance of diabetes mellitus in patients with liver cirrhosis. Taehan Kan Hakhoe Chi 9:205-211.
22. Li HC, Dehal SS, and Kupfer D (1995) Induction of the hepatic CYP2B and CYP3A enzymes by the proestrogenic pesticide methoxychlor and by DDT in the rats. Effect on methoxychlor metabolism. J Biochem Toxicol 10:51-61.
23. Lieber CS (1997) Cyloehrome P-4502E1: its physiological and pathological role. Physiol Rev 77:517-544.
24. Liu FT, Ioannides C, Shavila J, Symons AM, and Parke DV (1993) Effects of ether anaesthesia and fasting on various cytochromes P450 of rat liver and kidney. Biochem Pharmacol 45:871-877.
25. Mitruka BM and Rawnsley HM (1981) Clinical Biomedical and Hematological Reference Values in Normal Experimental Animals and Normal Humans, 2nd ed, Masson Publishing U S A Inc., New York.
26. Mizuno D, Tanaka E, Tanno K, and Misawa S (2000) Chlorzoxazone: a probe drug whose metabolism can be used to monitor toluene exposure in rats. Arch Toxicol 74:139-144.
27. Moon YJ, Lee AK, Chung HJ, Kim EJ, Kim SH, Lee DC, Lee I, Kim SG, and Lee MG (2003) Effects of acute renal failure on the pharmacokinetics of chlorzoxazone in rats. Drug Metab Dispos 31:776-784.
28. Moscatiello S, Manini R, and Marehesini G (2007) Diabetes and liver disease: an ominous association. Nutr Metab Cardiovasc Dis 17:63-70.
29. 1 antibody improves survival rate following partial hepatectomy in cirrholie rats. Hepatol Res 24:174-183.
30. Ono S, Hatanaka T. Hotta H, Tsutsui M, Satoh T, and Gonzalez FJ (1995) Chlorzoxazone is metabolized by human CYP1A2 as well as by human CYP2E1. Pharmacogenetics 5:143-150.
31. Peter R, Bocker R, Beaune PH, Iwasaki M, Guengerich FP, and Yang CS (1990) Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450 2E1. Chem Res Toxicol 3:566-573.
32. Rockich K and Blouin R (1999) Effect of the acute-phase response on the pharmacokinetics of chlorzoxazone and cytochrome P-450 2E1 in vitro activity in rats. Drug Metab Dispos 27:1074-1077.
33. Shim HJ, Lee EJ, Kim SH, Kim SH, Yoo M, Kwon JW, Kim WB, and Lee MG (2000) Factors influencing the protein binding of a new phosphodiesterase V inhibitor, DA-8159, using an equilibrium dialysis technique. Biopharm Drug Dispos 21:285-291.
34. Shimada T, Tsumura F, and Tamazaki H (1999) Predietion of human liver microsomal oxidation of 7-ethoxycoumarin and chlorzoxazone with kinetic parameters of recombinant cytochrome P-450 enzymes. Drug Metab Dispos 27:1274-1280.
35. Sierra-Santoyo A, Hernadez M, Albores A, and Cebrian ME (2000) Sex-dependent regulation of hepatic cytochrome P-450 by DDT. Toxicol Sci 54:81-87.
36. Tu YY, Peng R, Chang ZF, and Yang CS (1983) Induction of a high affinity nitrosarnine demethylase in rat liver microsomes by acetone and isopropanol. Chem Biol Interact 44:247-260.
37. Vidal J, Ferrer JP, Esmatjes E, Salmeron JM, Gonzalez-Clemente JM, Gomis R, and Rodes J (1994) Diabetes mellitus in patients with liver cirrhosis. Diabetes Res Clin Pract 25:19-25.
38. Wang Z, Hall SD, Maya JF, Li L, Asghar A, and Gorski JC (2003) Diabetes mellitus increases the in vivo activity of cytochrome P450 2E1 in humans. Br J Clin Pharmacol 55:77-85.
39. Woodcraft KJ, Hafner MS, and Novak RF (2002) Insulin signaling in the transcriptional and posttranscriptional regulation of CYP2E1 expression. Hepatology 35:263-273.
40. Yamaoka K, Nakagawa T, and Uno T (1978) Application of the Akaike's information criterion in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 6:165-175.